Xtl Biopharmaceuticals Ltd Stock Shares Owned By Insiders
| XTLB Stock | USD 1.70 0.03 1.73% |
XTL Biopharmaceuticals Ltd fundamentals help investors to digest information that contributes to XTL Biopharmaceutica's financial success or failures. It also enables traders to predict the movement of XTL Stock. The fundamental analysis module provides a way to measure XTL Biopharmaceutica's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to XTL Biopharmaceutica stock.
XTL | Shares Owned By Insiders |
XTL Biopharmaceuticals Ltd Company Shares Owned By Insiders Analysis
XTL Biopharmaceutica's Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
More About Shares Owned By Insiders | All Equity Analysis
Insiders Shares | = | Executives Shares | + | Employees |
Current XTL Biopharmaceutica Shares Owned By Insiders | 5.00 % |
Most of XTL Biopharmaceutica's fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, XTL Biopharmaceuticals Ltd is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
XTL Shares Owned By Insiders Driver Correlations
Understanding the fundamental principles of building solid financial models for XTL Biopharmaceutica is extremely important. It helps to project a fair market value of XTL Stock properly, considering its historical fundamentals such as Shares Owned By Insiders. Since XTL Biopharmaceutica's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of XTL Biopharmaceutica's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of XTL Biopharmaceutica's interrelated accounts and indicators.
Click cells to compare fundamentals
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
| Competition |
Based on the latest financial disclosure, 5.0% of XTL Biopharmaceuticals Ltd are shares owned by insiders. This is 67.06% lower than that of the Biotechnology sector and 64.74% lower than that of the Health Care industry. The shares owned by insiders for all United States stocks is 50.45% higher than that of the company.
XTL Shares Owned By Insiders Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses XTL Biopharmaceutica's direct or indirect competition against its Shares Owned By Insiders to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of XTL Biopharmaceutica could also be used in its relative valuation, which is a method of valuing XTL Biopharmaceutica by comparing valuation metrics of similar companies.XTL Biopharmaceutica is currently under evaluation in shares owned by insiders category among its peers.
XTL Biopharmaceutica Current Valuation Drivers
We derive many important indicators used in calculating different scores of XTL Biopharmaceutica from analyzing XTL Biopharmaceutica's financial statements. These drivers represent accounts that assess XTL Biopharmaceutica's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of XTL Biopharmaceutica's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 69.9K | 156.7K | 170.4K | 66.6K | 5.1M | 5.4M | |
| Enterprise Value | (4.4M) | (3.5M) | (2.8M) | (2.0M) | 3.7M | 3.9M |
XTL Fundamentals
| Return On Equity | -0.13 | ||||
| Return On Asset | -0.14 | ||||
| Current Valuation | 7.65 M | ||||
| Shares Outstanding | 5.45 M | ||||
| Shares Owned By Insiders | 5.00 % | ||||
| Shares Owned By Institutions | 1.92 % | ||||
| Number Of Shares Shorted | 75.24 K | ||||
| Price To Earning | 4.50 X | ||||
| Price To Book | 3.91 X | ||||
| EBITDA | (764 K) | ||||
| Net Income | (1.78 M) | ||||
| Cash And Equivalents | 5.16 M | ||||
| Cash Per Share | 0.95 X | ||||
| Total Debt | 206 K | ||||
| Current Ratio | 31.26 X | ||||
| Book Value Per Share | 0.01 X | ||||
| Cash Flow From Operations | (707 K) | ||||
| Short Ratio | 2.39 X | ||||
| Earnings Per Share | (0.03) X | ||||
| Target Price | 30.0 | ||||
| Beta | 1.0 | ||||
| Market Capitalization | 9.43 M | ||||
| Total Asset | 2.43 M | ||||
| Retained Earnings | (158.25 M) | ||||
| Working Capital | 1.84 M | ||||
| Current Asset | 3 M | ||||
| Net Asset | 2.43 M |
About XTL Biopharmaceutica Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze XTL Biopharmaceuticals Ltd's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of XTL Biopharmaceutica using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of XTL Biopharmaceuticals Ltd based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether XTL Biopharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of XTL Biopharmaceutica's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Xtl Biopharmaceuticals Ltd Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Xtl Biopharmaceuticals Ltd Stock:Check out XTL Biopharmaceutica Piotroski F Score and XTL Biopharmaceutica Altman Z Score analysis. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of XTL Biopharmaceutica. If investors know XTL will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about XTL Biopharmaceutica listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.76) | Earnings Share (0.03) | Return On Assets (0.14) | Return On Equity (0.13) |
The market value of XTL Biopharmaceuticals is measured differently than its book value, which is the value of XTL that is recorded on the company's balance sheet. Investors also form their own opinion of XTL Biopharmaceutica's value that differs from its market value or its book value, called intrinsic value, which is XTL Biopharmaceutica's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because XTL Biopharmaceutica's market value can be influenced by many factors that don't directly affect XTL Biopharmaceutica's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between XTL Biopharmaceutica's value and its price as these two are different measures arrived at by different means. Investors typically determine if XTL Biopharmaceutica is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, XTL Biopharmaceutica's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.